A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
复制标题
DOI：
10.1016/j.cgh.2014.07.055
复制
发表时间：
2015-03-01
影响因子：
12.6
通讯作者：
Ferrante, Marc
中科院分区：
文献类型：
--
作者：
Arias, Maria Theresa;Casteele, Niels Vande;Ferrante, Marc
背景与目的：英夫利昔单抗对难治性溃疡性结肠炎（UC）患者有效，但尚未确定预测治疗长期结果的因素。我们的目的是确定一组与英夫利昔单抗治疗结果相关的标志物，以帮助医生做出个性化的治疗决策。方法：我们收集了2012年7月前在比利时鲁汶大学医院接受英夫利昔单抗治疗的285例难治性UC患者（41%为女性，中位年龄39岁）的数据。我们进行了Cox回归分析，以确定预测无复发和无结肠切除生存的独立因素，并使用这些因素创建标记面板（风险面板）。结果：在中位随访5年期间，61%的患者复发，20%需要结肠切除术。无复发生存期的独立预测因子包括短期完全临床反应(优势比[OR]， 3.75； 95%可信区间[CI]， 2.35-5.97
BACKGROUND & AIMS: Infliximab is effective for patients with refractory ulcerative colitis (UC), but few factors have been identified that predict long-term outcome of therapy. We aimed to identify a panel of markers associated with outcome of infliximab therapy to help physicians make personalized treatment decisions.METHODS: We collected data from the first 285 patients with refractory UC (41% female; median age, 39 y) treated with infliximab before July 2012 at University Hospitals Leuven, in Belgium. We performed a Cox regression analysis to identify independent factors that predicted relapse-free and colectomy-free survival, and used these factors to create a panel of markers (risk panel).RESULTS: During a median follow-up period of 5 years, 61% of patients relapsed and 20% required colectomy. Independent predictors of relapse-free survival included short-term complete clinical response (odds ratio [OR], 3.75; 95% confidence interval [CI], 2.35-5.97; P